Review article · 2019 · Open access

On the mark: genetically engineered immunotherapies for autoimmunity

Christoph T. Ellebrecht, Daniel K. Lundgren, Aimee S. Payne

Current Opinion in Immunology, 61, 69–73 · Published 26 September 2019 · DOI 10.1016/j.coi.2019.08.005

Open full textView at the publisherCite this paper

In brief

“On the mark: genetically engineered immunotherapies for autoimmunity” is a 2019 review article by Christoph T. Ellebrecht and 2 co-authors, published in Current Opinion in Immunology. OpenAlex counts 12 citations as of 20 November 2026. It is open access: the full text is free to read at PubMed Central.

Citations
12
Most cited in
2020 (3)
Field-weighted impact
0.14
References
33
Authors
3

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Ellebrecht, C. T., Lundgren, D. K., & Payne, A. S. (2019). On the mark: genetically engineered immunotherapies for autoimmunity. Current Opinion in Immunology, 61, 69–73. https://doi.org/10.1016/j.coi.2019.08.005

MLA 9

Ellebrecht, Christoph T., et al. “On the mark: genetically engineered immunotherapies for autoimmunity.” Current Opinion in Immunology, vol. 61, 2019, pp. 69–73. https://doi.org/10.1016/j.coi.2019.08.005.

Chicago

Ellebrecht, Christoph T., Daniel K. Lundgren, and Aimee S. Payne. 2019. “On the mark: genetically engineered immunotherapies for autoimmunity.” Current Opinion in Immunology 61: 69–73. https://doi.org/10.1016/j.coi.2019.08.005.

Harvard

Ellebrecht, C. T., Lundgren, D. K. and Payne, A. S. (2019) ‘On the mark: genetically engineered immunotherapies for autoimmunity’, Current Opinion in Immunology, 61, pp. 69–73. doi:10.1016/j.coi.2019.08.005.

IEEE

C. T. Ellebrecht, D. K. Lundgren, and A. S. Payne, “On the mark: genetically engineered immunotherapies for autoimmunity,” Current Opinion in Immunology, vol. 61, pp. 69–73, 2019, doi: 10.1016/j.coi.2019.08.005.

BibTeX

@article{ellebrecht2019mark,
  title     = {{On the mark: genetically engineered immunotherapies for autoimmunity}},
  author    = {Ellebrecht, Christoph T. and Lundgren, Daniel K. and Payne, Aimee S.},
  journal   = {Current Opinion in Immunology},
  year      = {2019},
  volume    = {61},
  pages     = {69--73},
  doi       = {10.1016/j.coi.2019.08.005},
  url       = {https://doi.org/10.1016/j.coi.2019.08.005}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
201811
202033
202122
202222
202311
202422
202511

Its field-weighted citation impact is 0.14: it has been cited 0.14 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology

  • genetically modified T cells
  • adoptive immunotherapy
  • autoimmunity
  • autoreactive B cells
  • autoreactive T cells
  • B cell receptor
  • T cell receptor

Work with this paper

Most-cited papers in Immunology and Microbiology

All highly cited Immunology and Microbiology papers

Questions about this paper

How do I cite this paper in APA style?

Ellebrecht, C. T., Lundgren, D. K., & Payne, A. S. (2019). On the mark: genetically engineered immunotherapies for autoimmunity. Current Opinion in Immunology, 61, 69–73. https://doi.org/10.1016/j.coi.2019.08.005

How many times has this paper been cited?

12 times, according to OpenAlex on 20 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at PubMed Central: sign in and open the full text from this page.

Who wrote this paper?

Christoph T. Ellebrecht, Daniel K. Lundgren, Aimee S. Payne.

What is the DOI of this paper?

10.1016/j.coi.2019.08.005, permanently at https://doi.org/10.1016/j.coi.2019.08.005. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 20 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.